NCT06592560View on ClinicalTrials.gov

Asprosin in Breast Cancer

Not yet recruitingOBSERVATIONAL
Enrollment

84

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

October 31, 2025

Conditions
Breast Cancer
Interventions
DEVICE

ELISA

Specific test: Assay of asprosin marker will be measured by enzyme-linked immunosorbent assay ( ELISA).

All Listed Sponsors
lead

Marina Hanna Thabet Ghobrial

OTHER

NCT06592560 - Asprosin in Breast Cancer | Biotech Hunter | Biotech Hunter